Skip to main content
NewslettersWatchlist

Numinus Wellness Inc(NUMI-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0450
Day High0.0500
Open:0.0500
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
PR Newswire
Numinus Applies for Management Cease Trade Order
Baystreet
Stocks in play: Numinus Wellness Inc.
Newswire.ca
Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
AI-generated - The Globe and Mail
Numinus Wellness: Bottom 25 Performing Stocks Year-to-Date on TSX (NUMI)
Baystreet
Stocks in play: Numinus Wellness Inc.
Newswire.ca
Numinus Wellness Comments on FDA Decision on New Drug Application for MDMA-Assisted Therapy for PTSD
Baystreet
Stocks in play: Numinus Wellness Inc.
AI-generated - The Globe and Mail
Numinus Wellness: Bottom 25 Performing Stocks Year-to-Date on TSX (NUMI)
Newswire.ca
Numinus Wellness Inc. Announces Third Quarter Fiscal 2024 Results
Newswire.ca
Numinus to Host Q3 Fiscal 2024 Results Conference Call on July 11, 2024
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Healthcare Sector Stocks on TSX (NUMI)
Newswire.ca
Numinus Wellness Announces Resignation of Director
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Healthcare Providers & Services Industry Stocks (NUMI)
Baystreet
Stocks in play: Numinus Wellness Inc.
Newswire.ca
Numinus Wellness Announces Strategic Acquisition of MedBright AI
AI-generated - The Globe and Mail
Numinus Wellness: Bottom 25 Performing Stocks Year-to-Date on TSX (NUMI)
Newsfile
Numinus Clarifies Disclosures
Newswire.ca
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD
Newswire.ca
Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
AI-generated - The Globe and Mail
Numinus Wellness: Top 10 Undervalued Growth Stocks on TSX (NUMI)
Baystreet
Stocks in play: Numinus Wellness Inc.
Newsfile
Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder

Profile

Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.